SC TO-T/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO/A

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 4)

HealthTronics, Inc.

(Name of Subject Company (Issuer))

HT Acquisition Corp.

and

Endo Pharmaceuticals Holdings Inc.

(Names of Filing Persons (Offerors))

Common Stock, without par value

(Title of Class of Securities)

42222L107

(CUSIP Number of Class of Securities)

Caroline B. Manogue

Executive Vice President, Chief Legal Officer and Secretary

Endo Pharmaceuticals Holdings Inc.

100 Endo Boulevard

Chadds Ford, Pennsylvania 19317

(610) 558-9800

(Name, Address and Telephone Numbers of Person Authorized

to Receive Notices and Communications on Behalf of Filing Persons)

Copy to:

Eileen T. Nugent, Esq.

Brandon Van Dyke, Esq.

Skadden, Arps, Slate, Meagher & Flom LLP

4 Times Square

New York, New York 10036

(212) 735-3000

CALCULATION OF FILING FEE

Transaction Valuation(1)	Amount of Filing Fee(2)
$222,854,757.75	$15,889.54

(1) Estimated solely for purposes of calculating the filing fee. The transaction value was determined by adding (i) the product of (x) the offer price of $4.85 net per share in cash and (y) 45,630,810 shares of common stock, without par value (“Shares”) of HealthTronics, Inc. (“HealthTronics”) outstanding as of May 4, 2010 (including 1,785,230 Shares that were outstanding as of the relevant time but were subject to vesting or other forfeiture restrictions or a right of repurchase by Company as of such time), as represented by HealthTronics in the Merger Agreement (as defined herein) and (ii) the product of (x) 667,500 outstanding and unexercised options to acquire Shares with an exercise price of less than $4.85 per share as of May 4, 2010 and (y) the difference between (A) the offer price of $4.85 net per Share and (B) $2.5349, which represents the weighted average exercise price of the outstanding and unexercised options with an exercise price of less than $4.85 per share as of May 4, 2010.

(2) The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #5 for Fiscal Year 2010, issued March 10, 2010 by multiplying the transaction value by 0.00007130.

1

x Check the box if any part of the fee is offset as provided by Rule 0-11 (a) (2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: $15,889.54	Filing Party: HT Acquisition Corp. and Endo Pharmaceuticals Holdings Inc.
Form or Registration No.: Schedule TO	Date Filed: May 19, 2010

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

x third-party tender offer subject to Rule 14d-1.

¨ issuer tender offer subject to Rule 13e-4.

¨ going-private transaction subject to Rule 13e-3.

¨ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: x

This Amendment No. 4 (“Amendment No. 4”) amends the Tender Offer Statement on Schedule TO (“Schedule TO”) filed with the Securities and Exchange Commission on May 19, 2010, as amended on June 21, 2010, June 25, 2010 and July 2, 2010 by Endo Pharmaceuticals Holdings Inc., a Delaware corporation (“Endo”) and HT Acquisition Corp., a Georgia Corporation (“Purchaser”) and a direct, wholly owned subsidiary of Endo, which relates to the offer by Purchaser to purchase all outstanding shares of common stock, without par value (“Shares”), of HealthTronics, Inc., a Georgia corporation (“HealthTronics”), at a price of $4.85 per Share, net to the seller in cash less any required withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 19, 2010 (as it may be amended or supplemented from time to time, the “Offer to Purchase”) and in the related Letter of Transmittal (as it may be amended or supplemented from time to time, the “Letter of Transmittal” and, together with the Offer to Purchase, the “Offer”), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

This Amendment No. 4 is filed solely for the following purposes: to announce the results of the subsequent offering period, to announce the expiration of the subsequent offering period, to announce the merger of Purchaser and HealthTronics, and to supplement Item 12 with additional exhibits.

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“Endo Announces End of Subsequent Offering Period and Results of Offer

At 5:00 p.m., New York City time, on Friday, July 9, 2010, the subsequent offering period of the Offer expired. Based on preliminary information from American Stock Transfer & Trust Company, the depositary agent, as of the expiration of the subsequent offering period of the Offer, a total of 42,011,700 Shares were validly tendered and not withdrawn in the Offer, representing approximately 92.5% of the Shares outstanding.

On July 12, 2010, Endo issued a press release announcing that Purchaser has accepted for payment all Shares that were validly tendered during the subsequent offering period of the Offer. In addition, Endo announced that, to complete the acquisition of 100% of the Shares, Endo intended to effect a short-form merger in which Purchaser would be merged with and into HealthTronics, with HealthTronics surviving the merger and continuing as a wholly-owned subsidiary of Endo. The full text of the press release is attached as Exhibit (a)(5)(J) to the Schedule TO and is incorporated herein by reference.

On July 12, 2010, Purchaser completed its merger with HealthTronics, as a result of which HealthTronics has been acquired by, and is a wholly owned subsidiary of, Endo. The merger was effected pursuant to the Agreement and Plan of Merger, dated May 5, 2010, by and among Endo, Purchaser and HealthTronics. The common stock of HealthTronics ceased trading at market close on July 12, 2010 and each untendered share of common stock was converted into the right to receive $4.85 per HealthTronics share in cash.”

2

ITEM 12. EXHIBITS.

Item 12 of the Schedule TO is hereby amended and restated in its entirety as follows:

(a)(1)(A)*	Offer to Purchase, dated May 19, 2010
(a)(1)(B)*	Form of Letter of Transmittal
(a)(1)(C)*	Form of Notice of Guaranteed Delivery
(a)(1)(D)*	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
(a)(1)(E)*	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
(a)(1)(F)*	Internal Revenue Service Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form
(a)(1)(G)*	Press Release of Endo, dated May 5, 2010 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on May 6, 2010)
(a)(1)(H)*	Form of summary advertisement, published May 19, 2010 in The Wall Street Journal
(a)(2)	Not applicable
(a)(3)	Not applicable
(a)(4)	Not applicable
(a)(5)(A)*	Slide presentation relating to May 5, 2010 conference call (incorporated by reference to Exhibit 99.2 to the Form 8-K filed by Endo with the Securities and Exchange Commission on May 6, 2010)
(a)(5)(B)*	Script for conference call with Blaine T. Davis, David P. Holveck and James S.B. Whittenburg, dated May 5, 2010 (incorporated by reference to Exhibit 99.(a)(1) to the Schedule TO-C filed by Endo with the Securities and Exchange Commission on May 7, 2010)
(a)(5)(C)*	Article 13 of the Georgia Business Corporation Code
(a)(5)(D)*	Petition filed by Irving M. Pinkus C/F Gabriel P. Pinkus UTMA/IN in the District Court of Travis County in the State of Texas on May 11, 2010
(a)(5)(E)*	Petition filed by Nittin Namjoshi in District Court of Travis County in the State of Texas on May 13, 2010
(a)(5)(F)*	Petition filed by Anthony Cancelliere in the District Court of Travis County in the State of Texas on May 14, 2010
(a)(5)(G)*	HealthTronics’ Questions and Answers regarding the Merger, dated as of June 25, 2010
(a)(5)(H)*	Announcement to Endo Employees regarding HealthTronics Tender Offer closing, dated as of July 2, 2010
(a)(5)(I)*	Press Release of Endo, dated July 2, 2010 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on July 2, 2010)
(a)(5)(J)	Press Release of Endo, dated July 12, 2010
(b)	Not applicable
(d)(1)*	Agreement and Plan of Merger, dated as of May 5, 2010, by and among Endo, Purchaser and HealthTronics (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Endo with the Securities Exchange Commission on May 7, 2010)
(d)(2)*	Form of Shareholder Tender Agreement (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on May 7, 2010)
(d)(3)*	Confidentiality Agreement, dated as of March 2, 2010, by and between Endo and HealthTronics

3

(d)(4)*	Exclusivity Agreement, dated as of April 17, 2010, by and between Endo and HealthTronics
(g)	Not applicable
(h)	Not applicable

* Filed previously

ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.

Not applicable.

4

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Endo Pharmaceuticals Holdings Inc.
By:	/S/ CAROLINE B. MANOGUE
Name:	Caroline B. Manogue
Title:	Executive Vice President, Chief Legal Officer and Secretary
HT Acquisition Corp.
By:	/S/ CAROLINE B. MANOGUE
Name:	Caroline B. Manogue
Title:	Executive Vice President, Chief Legal Officer and Secretary

Dated: July 12, 2010

5

EXHIBIT INDEX

(a)(1)(A)*	Offer to Purchase, dated May 19, 2010
(a)(1)(B)*	Form of Letter of Transmittal
(a)(1)(C)*	Form of Notice of Guaranteed Delivery
(a)(1)(D)*	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
(a)(1)(E)*	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
(a)(1)(F)*	Internal Revenue Service Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form
(a)(1)(G)*	Press Release of Endo, dated May 5, 2010 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on May 6, 2010)
(a)(1)(H)*	Form of summary advertisement, published May 19, 2010 in The Wall Street Journal
(a)(2)	Not applicable
(a)(3)	Not applicable
(a)(4)	Not applicable
(a)(5)(A)*	Slide presentation relating to May 5, 2010 conference call (incorporated by reference to Exhibit 99.2 to the Form 8-K filed by Endo with the Securities and Exchange Commission on May 6, 2010)
(a)(5)(B)*	Script for conference call with Blaine T. Davis, David P. Holveck and James S.B. Whittenburg, dated May 5, 2010 (incorporated by reference to Exhibit 99.(a)(1) to the Schedule TO-C filed by Endo with the Securities and Exchange Commission on May 7, 2010)
(a)(5)(C)*	Article 13 of the Georgia Business Corporation Code
(a)(5)(D)*	Petition filed by Irving M. Pinkus C/F Gabriel P. Pinkus UTMA/IN in the District Court of Travis County in the State of Texas on May 11, 2010
(a)(5)(E)*	Petition filed by Nittin Namjoshi in District Court of Travis County in the State of Texas on May 13, 2010
(a)(5)(F)*	Petition filed by Anthony Cancelliere in the District Court of Travis County in the State of Texas on May 14, 2010
(a)(5)(G)*	HealthTronics’ Questions and Answers regarding the Merger, dated as of June 25, 2010
(a)(5)(H)*	Announcement to Endo Employees regarding HealthTronics Tender Offer closing, dated as of July 2, 2010
(a)(5)(I)*	Press Release of Endo, dated July 2, 2010 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on July 2, 2010)
(a)(5)(J)	Press Release of Endo, dated July 12, 2010
(b)	Not applicable
(d)(1)*	Agreement and Plan of Merger, dated as of May 5, 2010, by and among Endo, Purchaser and HealthTronics (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Endo with the Securities Exchange Commission on May 7, 2010)
(d)(2)*	Form of Shareholder Tender Agreement (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Endo with the Securities and Exchange Commission on May 7, 2010)
(d)(3)*	Confidentiality Agreement, dated as of March 2, 2010, by and between Endo and HealthTronics
(d)(4)*	Exclusivity Agreement, dated as of April 17, 2010, by and between Endo and HealthTronics
(g)	Not applicable
(h)	Not applicable

* Filed previously

6

EX-99.(A)(5)(J)

Exhibit 99.(a)(5)(J)

	CONTACT:
Investors/Media	Media
Blaine Davis	Kevin Wiggins
(610) 459-7158	(610) 459-7281
Investors
Jonathan Neely
(610) 459-6645

ENDO PHARMACEUTICALS ANNOUNCES EXPIRATION OF SUBSEQUENT

OFFERING PERIOD OF TENDER OFFER FOR HEALTHTRONICS, INC.

CHADDS FORD, Pa., July 12, 2010 – Endo Pharmaceuticals (NASDAQ: ENDP) today announced the expiration of the subsequent offering period of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc. (NASDAQ: HTRN). American Stock Transfer & Trust Company, the depositary for the tender offer, has advised Endo that, as of 5:00 p.m., New York City time, on July 9, 2010, the expiration of the subsequent offering period, approximately 42,011,700 shares were validly tendered and not withdrawn in the tender offer, representing approximately 92.5% of HealthTronics’ issued and outstanding shares. Endo has accepted for payment and promptly paid for all shares validly tendered during the subsequent offering period.

Endo also announced that, to complete the acquisition of 100% of the common stock of HealthTronics, Endo will effect, without prior notice to, or any action by, any other HealthTronics stockholder, a short-form merger in which HT Acquisition Corp. will merge with and into HealthTronics, with HealthTronics surviving the merger and continuing as a wholly owned subsidiary of Endo. In the merger, each of the remaining untendered shares of HealthTronics common stock (other than shares as to which appraisal rights are properly demanded and perfected under Georgia law, if any) will be converted into the right to receive the same $4.85 per HealthTronics share, in cash, as

was paid to HealthTronics’ stockholders pursuant to the tender offer. The merger is expected to occur later today and a subsequent press release will be issued upon consummation of the merger. Following the merger, HealthTronics’ common stock will cease to be traded on the NASDAQ Stock Market.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren(R) Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS(R) for the palliative treatment of advanced prostate cancer; SUPPRELIN(R) LA for the treatment of early onset puberty in children; and VALSTAR(TM) for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.